Mechanisms of cyclin-dependent kinase inactivation by progestins

Molecular and Cellular Biology

Volumn 18, Issue 4, 1998, Pages 1812-1825

  Musgrove, Elizabeth A ^a,b   Swarbrick, Alexander ^a   Lee, Christine S L ^a   Cornish, Ann L ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROGESTERONE;

ARTICLE; BREAST CARCINOGENESIS; CANCER RISK; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENZYME INACTIVATION; GROWTH INHIBITION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE DEPENDENCE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031949430     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.4.1812     Document Type: Article

References (66)

1. 1-arrested human breast cancer cells. Oncogene 12:2315-2324.
2. Aprelikova, O., Y. Xiong, and E. T. Liu. 1995. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem. 270: 18195-18197.
3. Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272:25863-25872.
4. Buckley, M. F., K. J. E. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland. 1993. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
5. Clarke, C. L., and R. L. Sutherland. 1990. Progestin regulation of cellular proliferation. Endocr. Rev. 11:266-302.
6. Colditz, G. A., S. E. Hankinson, D. J. Hunter, W. C. Willett, J. E. Manson, M. J. Stampfer, C. Hennekens, B. Rosner, and F. E. Speizer. 1995. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1589-1593.
7. Collaborative Group on Hormonal Factors in Breast Cancer. 1996. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727.
8. Collaborative Group on Hormonal Factors in Breast Cancer. 1997. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047-1059.
9. Coppola, J. A., B. A. Lewis, and M. D. Cole. 1990. Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. Oncogene 5:1731-1733.
10. Dubik, D., T. C. Dembinski, and R. P. C. Shiu. 1987. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47:6517-6521.
11. Foster, J. S., and J. Wimalasena. 1996. Estrogen regulated activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10:488-498.
12. Fotedar, R., P. Fitzgerald, T. Rouselle, D. Cannella, M. Dorée, H. Messier, and A. Fotedar. 1996. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155-2164.
13. Gabrielli, B. G., C. P. C. De Souza, I. D. Tonks, J. M. Clark, N. K. Hayward, and K. A. O. Ellem. 1996. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell Sci. 109:1081-1093.
14. Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382:511-517.
15. Gu, Y., J. Rosenblatt, and D. O. Morgan. 1992. Cell cycle regulation of CDK2 activity by phosphorylation of threonine 160 and tyrosine 15. EMBO J. 11:3995-4005.
16. Hanson, K. D., M. Shichiri, M. R. Follansbee, and J. M. Sedivy. 1994. Effects of c-myc expression on cell cycle progression. Mol. Cell. Biol. 14:5748-5755.
17. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
18. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowlski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
19. 1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 8:1759-1771.
20. WAF1/CIP1/SDI1. Oncogene 11:1409-1415.
21. Hirai, H., M. F. Roussel, J.-Y. Kato, R. A. Ashmun, and C. J. Sherr. 1995. Novel INK4 proteins, p19 and p18, arc specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
22. 1/S transition. EMBO J. 13:4302-4310.
23. co human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res 45: 167-173.
24. Hunter, T., and J. Pines. 1994. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79:573-582.
25. Iacobelli, S., G. Sica, C. Natoli, and D. Gatti. 1983. Inhibitory effects of medroxyprogesterone acetate on the proliferation of human breast cancer cells, p. 1-6. In L. Campio, G. Robustelli della Cuna, and R. W. Taylor (ed.), Role of medroxyprogesterone in endocrine-related tumors. Raven Press New York, N.Y.
26. Iavarone, A., and J. Massagué. 1997. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387:417-422.
27. Jinno, S., K. Suto, A. Nagata, M. Igarashi, Y. Kanaoka, H. Nojima, and H. Okayama. 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-1556.
28. Kalkhoven, E., L. Kwakkenbos-Isbrücker, C. L. Mummery, S. W. de Laat, A. J. M. van den Eijnen-van Raij, P. T. van der Saag, and B. van der Burg. 1995. The role of TGF-β production in growth inhibition of breast-tumor cells by progestins. Int. J. Cancer 61:80-86.
29. Kitagawa, M., H. Higashi, H.-K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J.-Y. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15:7060-7069.
30. LaBauer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
31. CDC25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci USA 88:10500-10504.
32. Morgan, D. O. 1995. Principles of CDK regulation. Nature 374:131-134.
33. Morgan, D. O. 1996. The dynamics of cyclin dependent kinase structure. Curr. Opin. Cell Biol. 8:767-772.
34. Müller, D., C. Bouchard, B. Rudolph, P. Steiner, I. Stuckmann, R. Saffrich, W. Ansorge, W. Huttner, and M. Eilers. 1997. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15:2561-2576.
35. Musgrove, E. A., J. A. Hamilton, C. S. L. Lee, K. J. E. Sweeney, C. K. W. Watts, and R. L. Sutherland. 1993. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577-3587.
36. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA 91:8022-8026.
37. Musgrove, E. A., C. S. L. Lee, A. L. Cornish, A. Swarbrick, and R. L. Sutherland. 1997. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the CDK inhibitor p21. Mol. Endocrinol. 11:54-66.
38. Musgrove, E. A., C. S. L. Lee, and R. L. Sutherland. 1991. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11:5032-5043.
39. Musgrove, E. A., B. Sarcevic, and R. L. Sutherland. 1996. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60:362-377.
40. Musgrove, E. A., and R. L. Sutherland. 1994. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5:381-389.
41. Kip1 binding to newly formed complexes. Oncogene 14:2373-2381.
42. Poon, R. Y. C., H. Toyoshima, and T. Hunter. 1995. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell 6:1197-1213.
43. Prall, O. W. J., E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland. Submitted for publication.
44. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272:10882-10894.
45. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11:492-503.
46. Rose, P. G. 1996. Endometrial cancer. N. Engl. J. Med. 335:640-649.
47. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331.
48. CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. Mol. Cell. Biol. 17:4338-4345.
49. Santen, R. J., A. Manni, H. Harvey, and C. Redmond. 1990. Endocrine treatment of breast cancer in women. Endocr. Rev. 11:221-265.
50. Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
51. Sherr, C. J., and J. M. Roberts. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
52. Slack, R. S., P. A. Hamel, T. S. Bladon, R. M. Gill, and M. W. McBurney. 1993. Regulated expression of the retinoblastoma gene in differentiating embryonal carcinoma cells. Oncogene 8:1585-1591.
53. Soos, T. J., H. Kiyokawa, J. S. Yan, M. S. Rubin, A. Giordano, A. DeBlasio, S. Bottega, B. Wong, J. Mendelsohn, and A. Koff. 1996. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7:135-146.
54. 1 cyclin-cdk complexes. EMBO J 14:4814-4826.
55. Sutherland, R. L., R. E. Hall, G. Y. N. Pang, E. A. Musgrove, and C. L. Clarke. 1988. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48:5084-5091.
56. 1 cyclin expression in breast cancer cells. Oncogene, in press.
57. Szekely, L., W. Q. Jiang, F. Bulic-Jakus, A. Rosen, N. Ringertz, G. Klein, and K. G. Wiman. 1992. Cell type and differentiation dependent heterogeneity in retinoblastoma protein expression in SCID mouse fetuses. Cell Growth Differ. 3:149-156.
58. Terada, Y., M. Tatsuka, S. Jinno, and H. Okayama. 1995. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. Nature 376:358-362.
59. 0-like arrest. Mol. Cell. Biol. 16:3934-3944.
60. Veronesi, U., A. Goldhirsch, and J. Yarnold. 1995. Breast cancer, p. 1243-1289. In M. Peckham, H. M. Pinedo, and U. Veronesi (ed.), Oxford textbook of oncology. Oxford University Press, Oxford, United Kingdom.
61. Vignon, F., S. Bardon, D. Chalbos, and H. Rochefort. 1983. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56:1124-1130.
62. Kip1 is abrogated by c-Myc. EMBO J. 15:6595-6604.
63. Wang, J. Y. J. 1997. Retinoblastoma protein in growth suppression and death protection. Curr. Opin. Genet. Dev. 7:39-45.
64. Watts, C. K. W., A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland. 1995. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9:1804-1813.
65. Wong, M. S. J., and L. C. Murphy. 1991. Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 39:39-44.
66. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.